Sugi Predict

Sugi Predict / Compounds / SCHEMBL21767534

SCHEMBL21767534

SCHEMBL21767534

COC(=O)Cc1cc(F)ccc1C1=CCOC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 1/20 0.36
▸ SCN9A Q15858 2/20 0.35
▸ ALDH1A1 P00352 7/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ GLA P06280 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ CCNT1 O60563 2/20 0.34
▸ CDK9 P50750 2/20 0.34
▸ GAA P10253 4/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ HTT P42858 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26049567 0.75 ALDH1A1 (0.36) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL31071954 0.74 ALDH1A1 (0.36) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL21767445 0.74 ALDH1A1 (0.36) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL24097694 0.73 EGFR (0.55) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL21767537 0.72 METAP2 (0.43) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL31071945 0.72 METAP2 (0.43) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL8063678 0.72 MAPK8 (0.46) ALDH1A1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL14186623 0.72 GAA (0.46) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL8251121 0.70 SMN1; SMN2 (0.43) ALDH1A1KDM4EGLAHPGDSMN1; SMN2
SCHEMBL23362766 0.70 SMN1; SMN2 (0.52) ALDH1A1HPGDSMN1; SMN2GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459942-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-11-04 — — US disclosed
US-20240376095-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN SCHR¿DINGER, LLC 2024-11-14 — — US disclosed
US-11739087-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-08-29 — — US disclosed
US-11739087-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-08-29 — — US disclosed
US-11739087-B2 Inhibiting (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-08-29 — — US disclosed
EP-4086254-A1 INTEGRIN INHIBITORS Morphic Therapeutic, Inc. (US) 2022-11-09 — — EP disclosed
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2022-03-10 — — US disclosed
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2022-03-10 — — US disclosed
US-11021480-B2 Inhibiting (α-V)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-01 — — US disclosed
US-11021480-B2 Inhibiting (α-V)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-01 — — US disclosed
US-20200385384-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN SCHRÖDINGER, LLC 2020-12-10 — — US disclosed
US-20200385384-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN SCHRÖDINGER, LLC 2020-12-10 — — US disclosed
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-11-12 — — US disclosed
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-11-12 — — US disclosed
US-20200071322-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-03-05 — — US disclosed
WO-2020047239-A1 INHIBITING αV β6 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2020-03-05 — — WO disclosed
WO-2020047239-A1 INHIBITING αV β6 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2020-03-05 — — WO disclosed
US-20200071322-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-03-05 — — US disclosed
EP-3617206-A1 INTEGRIN INHIBITORS Morphic Therapeutic, Inc. (US) 2020-03-04 — — EP disclosed
EP-3617206-A1 INTEGRIN INHIBITORS Morphic Therapeutic, Inc. (US) 2020-03-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459942-B2 Inhibiting (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV KLKB1 967/4885SCN9A 164/4885ALDH1A1 1629/4885
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KLKB1 845/4885SCN9A 168/4885ALDH1A1 1504/4885
US-20200071322-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KLKB1 845/4885SCN9A 168/4885ALDH1A1 1504/4885
US-20240376095-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KLKB1 845/4885SCN9A 168/4885ALDH1A1 1504/4885
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KLKB1 845/4885SCN9A 168/4885ALDH1A1 1504/4885
US-20200385384-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV KLKB1 845/4885SCN9A 168/4885ALDH1A1 1504/4885
US-11021480-B2 Inhibiting (α-V)(β-6) integrin ITGB6, ITGA6, ITGAV KLKB1 967/4885SCN9A 164/4885ALDH1A1 1629/4885
US-11739087-B2 Inhibiting (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV KLKB1 967/4885SCN9A 164/4885ALDH1A1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.